Zimycan "Not Approvable" Letter Could Mean One-Year Delay In Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's concerns stem from Barrier Therapeutics' use of a different grade of petrolatum in the absorption study than in clinical trials for the diaper dermatitis agent. The firm says conducting an additional study would take two to four months, plus six months for an agency review.